Literature DB >> 3355894

A new procoagulant in acute leukemia.

A Falanga1, M G Alessio, M B Donati, T Barbui.   

Abstract

To verify whether cancer procoagulant (CP), a cysteine proteinase procoagulant distinct from tissue factor (TF), is associated with leukemic cells, we assayed the procoagulant activity of blast cell extracts from 26 patients with different cytological subtypes of acute nonlymphoid leukemia (ANLL) according to the French-American-British classification. All the samples except two shortened the recalcification time of normal human plasma, the effect being significantly greater in the M3 subgroup. The two criteria used to distinguish between CP and TF, independence from factor VII in initiating blood coagulation and sensitivity to cysteine-proteinase inhibitors, were positive in 19 samples from M1, M2, M3, and M4 cytological subtypes. None of the M5 samples fulfilled these criteria. In addition, M1, M2, M3, and M4 samples immunoreacted with an anti-CP goat polyclonal antibody on an Ouchterlony immunodiffusion plate. This study provides the first evidence for a procoagulant other than TF that is associated with leukemic cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355894

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Non-tissue factor procoagulants in cancer cells.

Authors:  S G Gordon; M Chelladurai
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 2.  Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.

Authors:  M Shoji; W W Hancock; K Abe; C Micko; K A Casper; R M Baine; J N Wilcox; I Danave; D L Dillehay; E Matthews; J Contrino; J H Morrissey; S Gordon; T S Edgington; B Kudryk; D L Kreutzer; F R Rickles
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

Review 3.  Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.

Authors:  Maximilian Stahl; Martin S Tallman
Journal:  Leuk Lymphoma       Date:  2019-12-16

Review 4.  Pathogenesis of thrombosis in patients with malignancy.

Authors:  A Falanga; M B Donati
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

5.  Transient ischemic attack as an unusual initial manifestation of acute promyelocytic leukemia.

Authors:  Lifeng Liu; Xiaoling Yuan
Journal:  Int J Hematol       Date:  2016-03-16       Impact factor: 2.490

Review 6.  Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2020-09-09       Impact factor: 2.490

Review 7.  Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

Authors:  Nicole M Kuderer; Thomas L Ortel; Charles W Francis
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

8.  Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation.

Authors:  T Ogiichi; Y Hirashima; S Nakamura; S Endo; M Kurimoto; A Takaku
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

Review 9.  Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2013-11-12       Impact factor: 2.490

Review 10.  Hemostatic alterations in cancer patients.

Authors:  F R Rickles; M Levine; R L Edwards
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.